Form 4 for ENGN enGene Therapeutics Inc.
Accepted 2024-11-01 00:00:00 ET · period of report 2024-10-30 · accession 0000950170-24-120079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-01 | 2024-10-30 | ENGN | Forbion Growth Management B.V. | 10% | P - Purchase | $8.90 | +561.8K | 3.03M | +23% | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-10-30 | P | A | 561,797 | $8.90 | 3,032,430 | D | — | — | (F2) Shares held by Forbion Cooperatief. Forbion Growth Management B.V. ("Forbion Management") is the sole director of Forbion Cooperatief and exercises voting and investment power through its investment committee (the "Management Investment Committee"), consisting of S. Slootweg, van Osch, G. J. Mulder, V. van Houten, D.A.F. Kersten, N.L. Luneborg, W.S.J. Joustra and J.M. Bos. None of the members of the Management Investment Committee has individual voting and investment power with respect to the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of its pecuniary interest therein, if any. |